MARYLAND PRESCRIPTION DRUG AFFORDABILITY STAKEHOLDER COUNCIL VIRTUAL MEETING Monday, April 29, 2024 Minutes

Agenda Item 1

Call to Order:

Co-Chair Lorriane Diana called the meeting to order at 2:03 PM

(Roll Call) Stakeholder Council Members Present: Angela Bryant, Steven Chen, Lorraine Diana, Sherita Hill-Golden, Jim Gutman, Deron Johnson, Greta Kessler, Barry Lipsy, Eric Morse, Marc Nicole, Shaun O'Brien, Hayley Park, Mandi Poplawski, Glenn Schneider, Kelly Schulz, Sean Tunis, Joseph Winn, Thea Williams

Agenda Item 2

February 26, 2024 Meeting Minutes

Co-Chair Diana asked for a motion to approve the February 26, 2024 meeting minutes as submitted. Shaun O'Brien made the motion, which Sean Tunis seconded, and the Stakeholder Council unanimously approved the minutes.

Action: Minutes APPROVED

Agenda Item 3

Opportunity for Public Comment

- Prior to the meeting, 13 written comments were received, provided to all PDASC members and posted to the Stakeholder Council page on the Board's website.
- Seven people provided oral comment:
 - 1. Shawn Kwatra, MD, Chair of Dermatology at University of Maryland, Agenda Item IV.
 - 2. Jen Laws, CEO, CANN, Agenda Item IV.
 - 3. Benjamin Lockshin, MD, Board Certified Dermatologist, Agenda Item IV.
 - 4. Catherine Kirk Robins, Deputy Director, Health Care for All, Agenda Item IV.
 - 5. Derek Spencer, Gilead Sciences, Agenda Item IV.
 - 6. Mary Jo Strobel, Executive Director, APFED, Agenda Item IV.
 - 7. Dr. Danita Tolson, Maryland State NAACP Health Chair, Agenda Item IV.

Agenda Item 4

Cost Review Process Update- Discussion of Drugs Referred to the Stakeholder Council Attachment A, Drugs Referred to the Stakeholder Council

Presentation

Dr. Andrew York discussed the current status of the Cost Review Study Process regarding the identification and selection of prescription drug products according to COMAR 14.01.04.03. The Stakeholder Council was asked to provide input regarding the eight (8) drugs referred by the Board. This feedback will be summarized by Board staff and presented to the Board at the May 20, 2024 meeting.

Discussion

Eighteen minutes was allocated for discussion on each drug. Co-Chair Marc Nicole explained the process if additional time was needed to complete the discussion regarding a particular drug; after the allotted time for discussion for a drug, Co-Chair Nicole asked for additional comments, and if no comments remained, closed out the discussion on that drug.

The PDASC discussed each of the eight drugs individually in the following order:

- 1. Biktarvy
- 2. Dupixent
- 3. Farxiga
- 4. Jardiance
- 5. Ozempic
- 6. Skyrizi
- 7. Trulicity
- 8. Vyvanse

PDASC members provided feedback on each drug. Staff responded to any specific questions regarding the process. Some main themes of discussion included therapeutic alternatives, patient assistance and rebate programs, the cost review study process methodology and structure, collective feedback for diabetes drugs, healthy equity, access, and Medicare Drug Pricing Negotiation timelines.

Because the discussion on each drug was concluded during the allotted time, the tentatively scheduled additional May 6, 2024 meeting was not needed.

Agenda Item 5

Administrative Update

- The next Board meeting will be held on May 20, 2024 at the Miller Senate Building in Annapolis, Maryland. The meeting will be live streamed on the Maryland General Assembly website and pre-registration is not required.
- Staff discussed the public comment period for the Drugs Referred to the Stakeholder Council and Therapeutic Alternatives.

Agenda Item 6

Co-Chair Update

Co-Chair Diana stated that the next PDASC meeting will be on Monday, June 24, 2024 at 2:00pm. The PDASC will continue to meet virtually in 2024.

Agenda Item 7

Adjournment

Co-Chair Nicole thanked everyone for their attendance and asked for a motion to adjourn the meeting. Jim Gutman made the motion which was seconded by Shaun O'Brien.

Meeting Adjourned at 4:11 PM